Navigation Links
CTI Appoints Monique Greer, Senior Vice President, Corporate Communications and Investor Relations

SEATTLE, Nov. 12, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, announced today the appointment of Monique Greer as Senior Vice President, Corporate Communications and Investor Relations.  Ms. Greer will be responsible for leading CTI's external and internal communications strategies and will report directly to James A. Bianco, M.D., President and Chief Executive Officer.

"Monique is a key hire to drive consistent communications globally, as we transition from a product development organization to a commercial organization," said James Bianco.  "She has an excellent reputation in the biotechnology industry for developing and executing strategic, results-driven communications programs that advance business objectives.  We believe Monique's recent hematology/oncology commercial experience, management discipline and entrepreneurial drive will serve CTI well as we execute on our global strategy to deliver results for both patients and shareholders."

Ms. Greer has more than 17 years' experience planning and implementing strategic biotech/healthcare corporate communications, investor and media relations, and advocacy relations programs in support of product development, commercialization and strategic initiatives.  Most recently, Ms. Greer was Vice President of Corporate Communications and Investor Relations for Allos Therapeutics, Inc. (recently acquired by Spectrum Pharmaceuticals).  Ms. Greer served previously as Senior Associate in the Corporate Communications and Investor Relations practice for WCG, a global communications agency, where she created and implemented integrated, strategic communications programs for the firm's clients in the United States and Europe.  She has also served as Senior Director, Corporate Communications and Investor Relations for Dendreon Corporation, as well as Director, Corporate Communications for Heska Corporation.  Ms. Greer received a bachelor of science in Business Administration from Northeastern University.

About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Sign up for email alerts and get RSS feeds at our Web site,

Ed Bell
T: 206.282.7100
F: 206.272.4434

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novel Cancer Immune Therapy Developer Oncos Therapeutics Appoints Experienced Industry Leader Frans Wuite as President and CEO
2. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
3. Insmed Appoints 15-Year Life Sciences Industry Veteran Andrew Drechsler as Chief Financial Officer
4. ViaCyte Appoints Steve Altman to its Board of Directors
5. Northwest Biotherapeutics Appoints Pharma Industry Veteran As CEO Of German Subsidiary
6. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
7. BioNeutral Group Appoints Mr. Mark Lowenthal as Chief Executive and President
8. BioNeutral Group Appoints A New Member to the Board of Directors
9. Western Carolina University, College of Business Appoints New Director of Entrepreneurship and Innovation
10. JG Finneran Associates Appoints Chebios as its Exclusive Distributor in Italy
11. Althea Technologies Appoints Dr. Dennis Fenton As Chairman Of Its Scientific Advisory Board
Post Your Comments:
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 /PRNewswire/ ... London (ICR) and University of ... tool to risk-stratify patients with multiple myeloma (MM), in a ... . The University of Leeds is ... Myeloma UK, and ICR will perform the testing services to ...
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM Life ... for the life sciences and healthcare industries, announces a presentation by Subbu Viswanathan ... The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a revolutionary ...
Breaking Biology Technology:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/18/2017)... 2017  Socionext Inc., a global expert in SoC-based imaging and ... the M820, which features the company,s hybrid codec technology. A demonstration ... Probe, Inc., will be showcased during the upcoming Medtec Japan at ... the Las Vegas Convention Center April 24-27. ... Click here for an ...
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):